2011

Should a PR firm or an interactive marketing agency be in charge of pharma social media campaigns?

The Death of the Traditional Pharma Salesman and the Birth of the 'Sales Cyborg.' eDetailing in one form or another seems to be making a comeback since the recession hit the drug industry in 2007 and 2008. Which is the 'chicken' and which is the 'egg'? Did the uptick in adoption of eDetailing technology lead to the recent layoff of pharma reps or were reps laid off because of the economy and subsequently replaced by machines?

Welcome to Volume 10, Issue #9 (18 MAY 2011) of Pharma Marketing News.

No doubt you've heard that as of August 15, 2011, Facebook opened up comments on ALL pharma pages with some exceptions. That means that the pharmaceutical industry will no longer be able to shut off comments on their Facebook pages.

Pharma companies need to drive maximum value out of products and they can't do that with a 'one-size-fits-all' cookie-cutter approach to deploying field forces. Brand managers will look to outsourced providers to take advantage of the expertise these providers can bring to the table. This article is a summary of an interview of Nancy Lurker, CEO of PDI, Inc., which provides promotional outsourced services to healthcare companies.

A conversation with Monique Levy, VP Research at Manhattan Research, about the changing pharma eDetailing landscape. Ms. Levy discusses how the online pharma promotion landscape has changed, and which types of programs garner the largest audience as well as how the rep relationship is evolving and the role of new technologies such as tablets.

Boehringer-Ingelheim (BI) stands out in its attempt to stand out from the social(ist) cookie-cutter crowd of pharma FB pages. Shows what you can do with dedicated resources and creativity.

All pharma companies face a communications crisis that rests on the changing role of the medical sales representative. This evolution has a direct impact on the obligations of the pharma marketing organizations to be both proactive and responsive in helping to protect their organizations from the threat of non-compliance. What can marketing do? This article offers a few thoughts from a physician's point.

According to a recent CDC Data Brief, antidepressants were the third most common prescription drug taken by Americans of all ages in 2005–2008 and the most frequently used by persons aged 18–44 years. From 1988–1994 through 2005–2008, the rate of antidepressant use in the United States among all ages increased nearly 400%. Perhaps not so coincidentally, antidepressants are among the TOP advertised Rx category in 2010, according to the recent AdAge analysis.

Let's look 'under the hoods' of two pharma-sponsored mobile apps and compare disclaimers. We'll compare Janssen's PASI calculator, which has an update disclaimer, with the new AFib Educator 2.0 app developed by Sanofi-Aventis.